Breathe Well Live Well
Conditions: Cardiovascular Disease; Diabetes Type II; Breast Cancer; Asthma
Intervention: Other: Novartis Access
Sponsors: Boston University; Innovations for Poverty Action
Not yet recruiting – verified May 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Lupin to co-market Novartis' asthma drug in India
Business Standard Lupin Limited and Novartis Healthcare Private Limited (NHPL) yesterday entered into a co-marketing agreement to promote Novartis's indacaterol/glycopyrronium (110 mcg/50 mcg) inhaler, a treatment for chronic obstructive pulmonary disease (COPD), … |
View full post on asthma – Google News
|
Advera Health: Novartis, GSK asthma meds linked to more side effects than …
FiercePharma Healthcare informatics firm Advera Health Analytics scoured FDA postmarketing safety reports to compile data on side effects for companies producing asthma meds. Advera uses a reporting odds ratio (ROR) to compare the actual number of side effects … |
View full post on asthma – Google News
PMLiVE |
CHMP backs GSK's asthma antibody and Novartis' heart failure drug
PMLiVE GlaxoSmithKline's mepolizumab for severe asthma and Novartis new' heart failure therapy Entresto have been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The panel issued positive opinions for the two drugs … |
View full post on asthma – Google News
|
In late-stage study, Novartis finds asthma drug effective at reducing itch …
MedCity News ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study. The third and … |
View full post on asthma – Google News
French Tribune |
Novartis says asthma blockbuster Xolair also effective against serious hives
FiercePharma But Novartis says in financial filings that its pricing is under pressure for the asthma treatment. In the U.K., the price watchdog NICE last fall indicated it might drop approval of the drug there but then relented in March after Novartis offered up … Novartis reports new Phase III data showing omalizumab significantly improves … Novartis skin drug helps patients with chronic hives Novartis' omalizumab effective for severe hives |
View full post on asthma – Google News
|
NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd …
Big News Network.com asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million … |
View full post on asthma – Google News
|
NICE U-turn on Novartis' Xolair for asthma
PharmaTimes The National Institute for Health and Clinical Excellence said it now recommends Xolair (omalizumab) as an option for treating severe, persistent allergic asthma in adults, adolescents and children, in a complete turnaround from its earlier intention … Asthma treatment – double U-turn Life-changing jab gives hope to asthma sufferers NICE approves use of asthma drug omalizumab |
View full post on asthma – Google News
|
UK health cost body backs Novartis asthma drug in fresh U-turn
Chicago Tribune LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … Life-changing jab gives hope to asthma sufferers Asthma treatment – double U-turn NICE U-turn on Novartis' Xolair for asthma |
View full post on asthma – Google News
 Yahoo! News (blog) |
NICE backs Novartis asthma drug in fresh U-turn
Yahoo! News (blog) LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health … |
View full post on asthma – Google News